睿知中国医院研究地图
候选清单

即将招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06996093,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Early-stage breast cancer, with postoperative pathology confirming invasive carcinoma, HR-positive and HER2-negative (In this study, HR-positive is defined as: ER-positive by IHC with >10% tumor cells staining positive; HER2-negative defined as HER2 0-1+ by IHC or HER2++ with negative FISH result, without amplification);

    入选标准第 3 条

    Postoperative pathological stage pT2N0M0 and:

    入选标准第 4 条

  3. Men and women of childbearing potential unwilling to use contraception during treatment and for 8 weeks after treatment completion;

    排除标准第 11 条

  4. ECOG performance status 0-1;

    入选标准第 2 条

  5. Clinical or imaging suspicion of malignancy in the contralateral breast requiring biopsy (unless ruled out);

    排除标准第 3 条

    Use of tamoxifen, raloxifene, or aromatase inhibitors (AIs) for breast cancer risk reduction ("chemoprevention") and/or osteoporosis treatment within the past 2 years;

    排除标准第 5 条

    History of other malignancies within the past 5 years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix), including contralateral breast cancer;

    排除标准第 6 条

  6. Pregnant or lactating women;

    排除标准第 12 条

    Positive pregnancy test before study drug administration (for women of childbearing potential);

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06996093,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Females and males aged 18-70 years;
  2. ECOG performance status 0-1;
  3. Early-stage breast cancer, with postoperative pathology confirming invasive carcinoma, HR-positive and HER2-negative (In this study, HR-positive is defined as: ER-positive by IHC with >10% tumor cells staining positive; HER2-negative defined as HER2 0-1+ by IHC or HER2++ with negative FISH result, without amplification);
  4. Postoperative pathological stage pT2N0M0 and:
  5. No prior neoadjuvant therapy received;
  6. Good postoperative recovery, with randomization occurring no more than 8 weeks after surgery;
  7. Normal function of major organs, meeting the following criteria:
  8. Contraception required for male participants and women of childbearing potential during treatment;
  9. Participants voluntarily enroll in the study, sign informed consent, demonstrate good compliance, and cooperate with follow-up.

排除标准:Exclusion Criteria:

  1. Bilateral breast cancer or carcinoma in situ (DCIS/LCIS);
  2. Metastasis at any site;
  3. Clinical or imaging suspicion of malignancy in the contralateral breast requiring biopsy (unless ruled out);
  4. Prior neoadjuvant therapy, including chemotherapy, radiotherapy, or endocrine therapy;
  5. Use of tamoxifen, raloxifene, or aromatase inhibitors (AIs) for breast cancer risk reduction ("chemoprevention") and/or osteoporosis treatment within the past 2 years;
  6. History of other malignancies within the past 5 years (except basal cell carcinoma of the skin or carcinoma in situ of the cervix), including contralateral breast cancer;
  7. Concurrent participation in another clinical trial;
  8. Severe systemic diseases and/or uncontrolled infections that preclude study participation;
  9. Severe cardiovascular or cerebrovascular events within 6 months before randomization (e.g., unstable angina, chronic heart failure, uncontrolled hypertension >150/90 mmHg, myocardial infarction, or stroke);
  10. Known hypersensitivity to the study drugs;
  11. Men and women of childbearing potential unwilling to use contraception during treatment and for 8 weeks after treatment completion;
  12. Pregnant or lactating women;
  13. Positive pregnancy test before study drug administration (for women of childbearing potential);
  14. Psychiatric disorders, cognitive impairment, or inability to comprehend the trial protocol, adverse effects, or comply with study procedures and follow-up (requires systematic evaluation before enrollment);
  15. Individuals lacking personal freedom or legal capacity for independent civil conduct.

引自 ClinicalTrials.gov, NCT06996093, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06996093,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06996093